Bortezomib and zoledronate maintenance after autologous HSCT
SC indicates subcutaneous; IT, intensive therapy; NIT, nonintensive therapy; MV, multivariate; and ND, no difference.
Adapted from McCarthy et al.42
Sign In or Create an Account